PARP4 and cancer: To assess the consequence of the I1039T mutation in cancer, we compared the in vivo tumor-forming ability of iSAEC-K cells overexpressing either PARP4I1039T or PARP4WT in a clonal PARP4 knockout background (Fig. 2A, B).